The Human Protein Atlas Version 26

Danish Evaxion reports that all patients in its Phase 2 trial of the personalized cancer vaccine EVX-01 in advanced melanoma kept their clinical responses at the three-year follow-up, with no tumor progression observed.

Lars Fruergaard Jørgensen, who led Novo from 2017 to 2025, is set to become Chair of the Board of Lundbeck. He will join the board as an observer on November 10, 2026, and the board intends to appoint him Chair after the company's 2027 Annual General Meeting.

Danish Ascendis Pharma has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP), recommending EU approval of once-weekly TransCon CNP (navepegritide) for children with achondroplasia.

BioInvent has published results from the first clinical study of its anti-TNFR2 antibody BI-1808 in Clinical Cancer Research. In the Phase 1 dose escalation, no maximum tolerated dose was reached and all treatment-related side effects were grade 1 or 2.

Norwegian microbiome diagnostics company Genetic Analysis is presenting results today at UEG Week 2026 in Barcelona on GA-map IBD Precision Dx, a test designed to identify, at diagnosis, which ulcerative colitis patients are at risk of an aggressive disease course.

Calluna Pharma has completed dosing in its Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF). Topline results are expected in the first quarter of 2027.

Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.